Key points are not available for this paper at this time.
No takes yet. Share an insight, caveat, or question.
GPIIb/IIIa antagonists merit reevaluation as antiplatelet options; leaves open their role in current practice pending contemporary trials.
Coller et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: